Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
DNAG possible big move
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by ehya: [QB] NEWS: http://biz.yahoo.com/iw/060309/0112547.html Press Release Source: DNAPrint Genomics, Inc. Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc. Thursday March 9, 7:00 am ET SARASOTA, FL--(MARKET WIRE)--Mar 9, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Harvard University has received formal Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company. DNAPrint entered into an agreement with Harvard in January 2006 to sponsor continued research based on the marker, CD59, in the Harvard Medical School laboratory of Dr. Jose Halperin, a named inventor of the allowed claims. These claims, once issued, will provide Harvard additional intellectual property protection to support the development and commercialization by DNAPrint of new diagnostic tests to better define and manage diabetes more effectively. The studies conducted by Dr. Halperin and his Harvard Medical School colleagues indicate that CD59 becomes inactivated in the presence of high blood glucose levels observed in patients with diabetes, and thus does not function normally to protect blood vessel walls from inflammatory damage. This leads to the obstruction of the many small vessels that provide critical nutrients and oxygen to organs and tissues. The common vascular disease complications suffered by individuals with diabetes -- nephropathy, retinopathy, neuropathy and atherosclerotic heart disease -- are all believed to be caused by this vascular obstruction and destruction. A test to detect CD59 in its glycated, inactive form would be a specific warning that the patient has had poor glucose control and that vascular complications are developing even before clinical symptoms show irreversible tissue and organ damage. "Microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries are major reasons why medical costs are so high for patients with diabetes as well as causing unfortunate suffering for this group of patients of all ages," commented DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc. "Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar or glucose levels experienced by even well-controlled diabetes patients. Now we are able to move forward confidently with the development of our test, knowing that we have appropriate patent protection." "Approval of the latest patent claims represents a milestone for Dr. Jose Halperin of Harvard Medical School and his team," commented DNA Print President and Chief Executive Officer Richard Gabriel. "According to the Center for Disease Control and Prevention, the total direct and indirect cost for both type 1 and type 2 diabetes in the United States in 2002 (four years ago) was $132 billion. Our goal is to try to help patients with diabetes understand their disease earlier, and with this knowledge, attempt to minimize their physical complications as well as reduce the associated expense to the U.S. healthcare system. We also know from physician reports that diabetes is expressed more in some patient population groups than others, so coupling our new CD59 diagnostic with our genetic ancestry information will be a valuable tool in developing and understanding the CD59 diagnostic," he concluded. Details about the field-exclusive licensing agreement between DNAPrint Genomics, Inc. and Harvard University announced on January 26, 2006 can be found at: http://www.dnaprint.com/welcome/press/press_recent/2006/0126/ DNAG-HARVARD.pdf About DNAPrint Genomics, Inc. DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [URL=http://www.dnaprint.com]www.dnaprint.com[/URL] for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Contact: Company Contact: Richard Gabriel CEO and President (941) 366-3400 Ron Stabiner The Wall Street Group, Inc. (212) 888-4848 Source: DNAPrint Genomics, Inc. [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2